AC
NAUT icon

Aristides Capital’s Nautilus Biotechnolgy NAUT Stock Holding History

Aristides Capital’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,100
Closed -$187K – 255
2021
Q4 		$187K Buy
+36,100
New +$193K 0.09% 208

Other funds holding NAUT

AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
AEPLI
AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

Aristides Capital's NAUT Position: Q1 2022 in Review

Aristides Capital sold out of Nautilus Biotechnolgy (NAUT) in Q1 2022, closing a stake of 36,100 shares — an estimated $187K sold.

Aristides Capital first reported a position in NAUT in Q4 2021 and held it in 1 quarter. The position peaked at $187K in Q4 2021. 82 funds tracked by Wall St. Rank hold NAUT as of Q1 2022.

  • Aristides Capital reported no remaining Nautilus Biotechnolgy position as of Q1 2022 after selling out during the quarter.
  • Aristides Capital sold 36,100 Nautilus Biotechnolgy shares in Q1 2022, an estimated $187K.
  • Aristides Capital first reported a position in Nautilus Biotechnolgy in Q4 2021 and held it in 1 quarter.
  • Aristides Capital's Nautilus Biotechnolgy position peaked at $187K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.